Rare tumour team wins world class status
An Addenbrooke’s Hospital team dedicated to treating patients with rare tumours has today (Wed 2 June) been named as an official centre of excellence – making it one of just a handful across the world, and the first in the UK.
The Pheochromocytoma and Paraganglioma Group was awarded the coveted status by the Pheo Para Alliance, which is an internationally recognised leader in patient advocacy and raising awareness of the condition.
Management of the condition at Addenbrooke’s is led by a multi-disciplinary team including specialists in endocrine disorders, oncologists, radiation oncologists, specialist nurses, pathologists, nuclear medicine physicians, clinical geneticists, surgeons, anaesthetists, paediatric specialists and a number of other healthcare professionals.
Team leader and consultant endocrinologist, Dr Ruth Casey, who is based in Addenbrooke’s in the department of endocrinology, said: “We are one of a few centres internationally to receive this status so far so it is great news for us, the hospital, and most importantly our patients
“I want to say a massive ‘thank you’ to my colleagues for this team effort and to our patients for the positive feedback which is not only appreciated by us, but noted by those considering our application.”
Pheo Para Alliance board member and patient, Eli Soto, added: “Connecting patients to the exceptional team at Addenbrooke’s will provide them with hope and comfort they need during their pheo para journey.”
About Cambridge University Hospitals
Cambridge University Hospitals NHS Foundation Trust (CUH) is one of the largest and best known trusts in the country, delivering high-quality patient care through Addenbrooke’s and the Rosie Hospitals. CUH is a leading national centre for specialist treatment for rare or complex conditions and a university teaching hospital with a worldwide reputation.
CUH is a key partner in Cambridge University Health Partners (CUHP), one of only six academic health science centres in the UK, and is at the heart of the development of the Cambridge Biomedical Campus (CBC), which brings together on one site world-class biomedical research, patient care and education. As part of the Campus development, Papworth Hospital has created a bespoke, purpose-built hospital, and AstraZeneca is building a new global R&D centre and corporate headquarters. The Campus is one of the Government’s National Institute for Health Research (NIHR) comprehensive biomedical research centres.
CUH Communications Department
Tel: 07517 133031
More about Cambridge University Hospitals (CUH) visit: http://www.cuh.org.uk/